The Food and Drug Administration (FDA) has approved the dual-antiretroviral (ARV) combination tablet Temixys (lamivudine/tenofovir disoproxil fumarate), which is manufactured by South Korean biopharmaceutical company Celltrion Inc., Pulse reports.
The tablet, which is to be used in combination with at least one other ARV to treat HIV, is similar to Gilead Sciences’ Truvada (tenofovir disoproxil fumarate/emtricitabine). They both contain tenofovir disoproxil fumarate, which is manufactured as an individual tablet under the brand name Viread and is a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI). The second medications in each tablet are also NRTIs: Lamivudine (brand name Epivir) is in Temixys, and emtricitabine (brand name Emtriva) is in Truvada.
